Sudáfrica - inglés - South African Health Products Regulatory Authority (SAHPRA)

novartis south africa (pty) ltd - tablet - see ingredients - each tablet contains hydrochlorothiazide 25,0 mg valsartan 160,0 mg

Sudáfrica - inglés - South African Health Products Regulatory Authority (SAHPRA)

novartis south africa (pty) ltd - tablet - see ingredients - each tablet contains hydrochlorothiazide 12,5 mg valsartan 320,0 mg

Sudáfrica - inglés - South African Health Products Regulatory Authority (SAHPRA)

novartis south africa (pty) ltd - tablet - see ingredients - each tablet contains hydrochlorothiazide 25,0 mg valsartan 320,0 mg

Israel - inglés - Ministry of Health

novartis israel ltd - valsartan - film coated tablets - valsartan 80 mg - valsartan - valsartan - for treatment of hypertension. diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan signicantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Israel - inglés - Ministry of Health

novartis israel ltd - valsartan - film coated tablets - valsartan 160 mg - valsartan - valsartan - for treatment of hypertension. diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan signicantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Estados Unidos - inglés - NLM (National Library of Medicine)

stat rx usa llc - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th), valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - hydrochlorothiazide 12.5 mg - diovan hct (valsartan and hydrochlorothiazide, usp) is indicated for the treatment of hypertension. diovan hct may be used in patients whose blood pressure is not adequately controlled on monotherapy. diovan hct may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. the choice of diovan hct as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. individual blood pressure goals may vary based upon the patient’s risk. d

Malasia - inglés - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - valsartan; hydrochlorothiazide -

Malasia - inglés - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - valsartan; hydrochlorothiazide -

Estados Unidos - inglés - NLM (National Library of Medicine)

rebel distributors corp - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 80 mg - diovan® (valsartan) is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. diovan is indicated for the treatment of heart failure (nyha class ii-iv). in a controlled clinical trial, diovan significantly reduced hospitalizations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. [ see  clinical studies (14.2)]   in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction, diovan is indicated to reduce cardiovascular mortality. [ see  clinical studies (14.3 ) ] none teratogenic effects: pregnancy category d diovan, like other drugs that act on the renin angiotensin system, can cause fetal and neonatal morbidity and death when used during the second or third trimester of pregnancy. diovan can cause fetal harm when administered to a pregnant woman. if this drug is used during pregnancy, or if the p

Estados Unidos - inglés - NLM (National Library of Medicine)

physicians total care, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 40 mg - diovan® (valsartan) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with diovan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluati